Hypereosinophilic Syndrome: Lymphoproliferative and Myeloproliferative Variants

ABSTRACT

Idiopathic hypereosinophilic syndrome is a largely heterogeneous disorder defined as persistent, marked hypereosinophilia of unknown origin complicated by end-organ damage. Recent research in cellular and molecular biology has led to the characterization of distinct underlying hematological disorders, primitively involving cells of the myeloid or lymphoid lineage. The ability to classify many hypereosinophilic syndrome patients on the basis of pathogenesis of hypereosinophilia has radically changed therapeutic perspectives. Indeed, imatinib mesylate has become first-line therapy for patients in whom the FIP1L1-PDGFRα fusion gene is detected, whereas corticosteroids remain the mainstay for management of patients in whom hypereosinophilia is secondary to the overproduction of interleukin 5 by abnormal T-cells. Use of monoclonal anti-interleukin-5 antibodies in the latter group of patients has a strong rationale and could decrease cumulative corticosteroid doses and toxicity. As far as prognosis of these disease variants is concerned, hypereosinophilic syndrome patients with the FIP1L1-PDGFRα fusion gene may develop acute myelogenous (eosinophilic) leukemia, whereas those with clonal interleukin-5-producing T-cells have an increased risk of developing T-cell lymphoma. It is currently unclear whether timely therapeutic intervention in such patients could interfere with long-term progression toward malignant hematological disorders.

Lymphoma - IL-5 - FIP1L1-PDGFRα - CD3^-CD4⁺ T-cell - eosinophil

REFERENCES

• 1 Hardy W R, Anderson R E. The hypereosinophilic syndromes.  Ann Intern Med. 1968;  68 1220-1229
• 2 Chusid M J, Dale D C, West B C, Wolff S M. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.  Medicine (Baltimore). 1975;  54 1-27
• 3 Fauci A S, Harley J B, Roberts W C, Ferrans V J, Gralnick H R, Bjornson B H. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations.  Ann Intern Med. 1982;  97 78-92
• 4 Weller P F, Bubley G J. The idiopathic hypereosinophilic syndrome.  Blood. 1994;  83 2759-2779
• 5 Liapis H, Ho A K, Brown D, Mindel G, Gleich G. Thrombotic microangiopathy associated with the hypereosinophilic syndrome.  Kidney Int. 2005;  67 1806-1811
• 6 Flaum M A, Schooley R T, Fauci A S, Gralnick H R. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations.  Blood. 1981;  58 1012-1020
• 7 Schooley R T, Flaum M A, Gralnick H R, Fauci A S. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.  Blood. 1981;  58 1021-1026
• 8 Bain B J. Hypereosinophilia.  Curr Opin Hematol. 2000;  7 21-25
• 9 Wardlaw A J. Eosinophils in the 1990s: new perspectives on their role in health and disease.  Postgrad Med J. 1994;  70 536-552
• 10 Vowels B R, Cassin M, Vonderheid E C, Rook A H. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.  J Invest Dermatol. 1992;  99 90-94
• 11 Sanderson C J. Interleukin-5, eosinophils, and disease.  Blood. 1992;  79 3101-3109
• 12 Romagnani S. Th1 and Th2 in human diseases.  Clin Immunol Immunopathol. 1996;  80 225-235
• 13 Wassom D L, Loegering D A, Solley G O et al.. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia.  J Clin Invest. 1981;  67 651-661
• 14 Keene P, Mendelow B, Pinto M R et al.. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association.  Br J Haematol. 1987;  67 25-31
• 15 Luppi M, Marasca R, Morselli M, Barozzi P, Torelli G. Clonal nature of hypereosinophilic syndrome.  Blood. 1994;  84 349-350
• 16 Chang H W, Leong K H, Koh D R, Lee S H. Clonality of isolated eosinophils in the hypereosinophilic syndrome.  Blood. 1999;  93 1651-1657
• 17 Cools J, DeAngelo D J, Gotlib J et al.. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.  N Engl J Med. 2003;  348 1201-1214
• 18 Klion A D, Noel P, Akin C et al.. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.  Blood. 2003;  101 4660-4666
• 19 Vandenberghe P, Wlodarska I, Michaux L et al.. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.  Leukemia. 2004;  18 734-742
• 20 Griffin J H, Leung J, Bruner R J, Caligiuri M A, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.  Proc Natl Acad Sci USA. 2003;  100 7830-7835
• 21 Klion A D, Robyn J A, Akin C et al.. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.  Blood. 2004;  103 473-478
• 22 Bain B J. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias.  Br J Haematol. 2003;  122 173-179
• 23 Raghavachar A, Fleischer S, Frickhofen N, Heimpel H, Fleischer B. T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome.  J Immunol. 1987;  139 3753-3758
• 24 Schrezenmeier H, Thome S D, Tewald F, Fleischer B, Raghavachar A. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.  Exp Hematol. 1993;  21 358-365
• 25 Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.  N Engl J Med. 1994;  330 535-538
• 26 Simon H U, Plotz S G, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.  N Engl J Med. 1999;  341 1112-1120
• 27 Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes.  Allergy. 2004;  59 673-689
• 28 Roche-Lestienne C, Lepers S, Soenen-Cornu V et al.. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.  Leukemia. 2005;  19 792-798
• 29 Roufosse F, Schandene L, Sibille C et al.. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome.  Br J Haematol. 2000;  109 540-548
• 30 Simon H U, Yousefi S, Dommann-Scherrer C C et al.. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia.  J Exp Med. 1996;  183 1071-1082
• 31 Schandene L, Roufosse F, de Lavareille A et al.. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia.  Blood. 2000;  96 4285-4292
• 32 Willard-Gallo K E, Van de Keere F, Kettmann R. A specific defect in CD3 gamma-chain gene transcription results in loss of T-cell receptor/CD3 expression late after human immunodeficiency virus infection of a CD4+ T-cell line.  Proc Natl Acad Sci USA. 1990;  87 6713-6717
• 33 de Waal Malefyt R, Yssel H, Spits H et al.. Human T cell leukemia virus type I prevents cell surface expression of the T cell receptor through down-regulation of the CD3-gamma, -delta, -epsilon, and -zeta genes.  J Immunol. 1990;  145 2297-2303
• 34 Plotz S G, Simon H U, Darsow U et al.. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.  N Engl J Med. 2003;  349 2334-2339
• 35 Reinhold U, Liu L, Sesterhenn J, Abken H. CD7-negative T cells represent a separate differentiation pathway in a subset of post-thymic helper T cells.  Immunology. 1996;  89 391-396
• 36 Zenone T, Felman P, Malcus C, Durieu I, Durand D V. Indolent course of a patient with hypereosinophilic syndrome associated with clonal T-cell proliferation.  Am J Med. 1999;  107 509-511
• 37 Morgan S J, Prince H M, Westerman D A, McCormack C, Glaspole I. Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich's syndrome).  Leuk Lymphoma. 2003;  44 1623-1625
• 38 Spry C J, Davies J, Tai P C, Olsen E G, Oakley C M, Goodwin J F. Clinical features of fifteen patients with the hypereosinophilic syndrome.  Q J Med. 1983;  52 1-22
• 39 Winn R E, Kollef M H, Meyer J I. Pulmonary involvement in the hypereosinophilic syndrome.  Chest. 1994;  105 656-660
• 40 Cottin V, Cordier J F. Eosinophilic pneumonias.  Allergy. 2005;  60 841-857
• 41 Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited.  Annu Rev Med. 2003;  54 169-184
• 42 Ravoet M, Sibille C, Roufosse F et al.. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome.  Haematologica. 2005;  90 753-765
• 43 Lepretre S, Buchonnet G, Stamatoullas A et al.. Chromosome abnormalities in peripheral T-cell lymphoma.  Cancer Genet Cytogenet. 2000;  117 71-79
• 44 Thangavelu M, Finn W G, Yelavarthi K K et al.. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sezary syndrome.  Blood. 1997;  89 3371-3377
• 45 Kyoizumi S, Akiyama M, Hirai Y, Kusunoki Y, Tanabe K, Umeki S. Spontaneous loss and alteration of antigen receptor expression in mature CD4+ T cells.  J Exp Med. 1990;  171 1981-1999
• 46 Serke S, van Lessen A, Hummel M, Szczepek A, Huhn D, Stein H. Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma.  Cytometry. 2000;  42 180-187
• 47 Roufosse F, Schandene L, Sibille C et al.. T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia.  Blood. 1999;  94 994-1002
• 48 Pardanani A, Ketterling R P, Brockman S R et al.. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to Imatinib therapy.  Blood. 2003;  102 3093-3096
• 49 Brugnoni D, Airo P, Rossi G et al.. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5.  Blood. 1996;  87 1416-1422
• 50 Kitano K, Ichikawa N, Shimodaira S, Ito T, Ishida F, Kiyosawa K. Eosinophilia associated with clonal T-cell proliferation.  Leuk Lymphoma. 1997;  27 335-342
• 51 Roumier A S, Grardel N, Lai J L et al.. Hypereosinophilia with abnormal T cells, trisomy 7 and elevated TARC serum level.  Haematologica. 2003;  88 ECR24
• 52 de Lavareille A, Roufosse F, Schmid-Grendelmeier P et al.. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome.  J Allergy Clin Immunol. 2002;  110 476-479
• 53 Butterfield J H, Gleich G J. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome.  Ann Intern Med. 1994;  121 648-653
• 54 Savage D G, Antman K H. Imatinib mesylate-a new oral targeted therapy.  N Engl J Med. 2002;  346 683-693
• 55 Gleich G J, Leiferman K M, Pardanani A, Tefferi A, Butterfield J H. Treatment of hypereosinophilic syndrome with imatinib mesilate.  Lancet. 2002;  359 1577-1578
• 56 Rotoli B, Catalano L, Galderisi M et al.. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome.  Leuk Lymphoma. 2004;  45 2503-2507
• 57 Cools J, Stover E H, Boulton C L et al.. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease.  Cancer Cell. 2003;  3 459-469
• 58 Pardanani A, Reeder T, Porrata L F et al.. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.  Blood. 2003;  101 3391-3397
• 59 Pitini V, Arrigo C, Azzarello D et al.. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.  Blood. 2003;  102 3456-3457
• 60 Braun C M, Huang S K, Bashian G G, Kagey-Sobotka A, Lichtenstein L M, Essayan D M. Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses.  J Allergy Clin Immunol. 1997;  100 400-407
• 61 Sugimoto K, Tamayose K, Sasaki M et al.. More than 13 years of hypereosinophila associated with clonal CD3-CD4+ lymphocytosis of TH2/TH0 type.  Int J Hematol. 2002;  75 281-284
• 62 Schandene L, Del Prete G F, Cogan E et al.. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells.  J Clin Invest. 1996;  97 309-315
• 63 Sutton S A, Assa'ad A H, Rothenberg M E. Anti-IL-5 and hypereosinophilic syndromes.  Clin Immunol. 2005;  115 51-60
• 64 Garrett J K, Jameson S C, Thomson B et al.. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.  J Allergy Clin Immunol. 2004;  113 115-119
• 65 Klion A D, Law M A, Noel P, Kim Y J, Haverty T P, Nutman T B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.  Blood. 2004;  103 2939-2941
• 66 Kim Y J, Prussin C, Martin B et al.. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.  J Allergy Clin Immunol. 2004;  114 1449-1455
• 67 Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.  Br J Haematol. 2004;  127 477
• 68 Lundin J, Kennedy B, Dearden C, Dyer M J, Osterborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome.  Blood. 2005;  105 4148-4149
• 69 Aubin F, Salard D, Pouthier F et al.. La photochimiothérapie extracorporelle.  Med Sci (Paris). 1999;  15 983-989
• 70 Adkins J C, Peters D H, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.  Drugs. 1997;  53 1005-1037